Home/ Stocks/ VNDA

Vanda Pharmaceuticals Inc.

VNDA XNAS

$5.28 -0.12 (-2.23%) ▼ 15-min delayed

Open

$5.42

High

$5.42

Low

$5.26

Volume

656.8K

Market Cap

$319.24M

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 533 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$50.53M	$-62,513,000	$-1.04
Q1 2026	$51.72M	$-48,567,000	$-0.82
FY 2025	$216.10M	$-220,474,000	$-3.74
Q3 2025	$56.26M	$-22,586,000	$-0.38

TickerDaily Coverage

Why Is Vanda Pharmaceuticals (VNDA) Stock Up 36.1% Today?

Market News Alex Chen · Feb 23, 2026

Vanda Pharmaceuticals (VNDA) stock exploded 36.1% to $5.76, trading 4.8x its average volume of...

View All Coverage →

Get VNDA Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Vanda Pharmaceuticals Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.